The effects of an orally active inhibitor (UK 79300) of the neutral metalloendopeptidase EC 3.4.24.11 were investigated in six healthy male volunteers maintained on a constant diet (150 mmol sodium/day and 80 mmol potassium/day). Subjects were studied in a random order, single-blind study on two occasions, each 48 hours in length, when they were given UK 79300 (25 or 50 mg p.o.) or placebo at 12-hour intervals (each agent for 24 hours). The endopeptidase inhibitor enhanced plasma concentrations of atrial natriuretic factor in association with suppression of both plasma renin activity and aldosterone concentrations. Twenty-four-hour urinary excretion of sodium was doubled by UK 79300, and the urinary excretion rates of phosphorus, atrial natriuretic factor immunoreactivity, and cyclic guanosine monophosphate were also significantly enhanced, whereas urinary aldosterone excretion was halved. The profile of biological effects closely paralleled those previously reported with low dose infusions of atrial natriuretic factor in humans and animals. Therapeutic trials of such inhibitors are now indicated for hypertension or heart failure together with further studies to clarify the underlying mechanisms of action. {Hypertension 1990;16:269-276) A trial natriuretic factor (ANF) exhibits a broad / \ range of actions, all of which may be perti-/ % nent in volume-pressure homeostasis. In addition to natriuretic and diuretic activity, ANF inhibits the renin-angiotensin-aldosterone system (RAAS), contracts plasma volume by extrarenal mechanisms, and is a vasodilator. This spectrum of activity suggests ANF may have therapeutic potential in conditions such as hypertension and heart failure. Recent studies incorporating administration of very low or "physiological" doses of exogenous ANF to both normal volunteers and patients with hypertension demonstrate the capacity of very small shifts in plasma concentrations of ANF to inhibit the RAAS, induce natriuresis, and with sustained administration, exert a salutary hypotensive effect in patients with essential hypertension. bond producing an open-ring structure, which our group has identified as being present in significant quantities in human plasma.
These findings have encouraged a widespread search for orally active agents such as analogues of ANF or, alternatively, inhibitors of ANF degradation for use in therapeutic trials. The cleavage of ANF-(99-126) by the neutral metalloendopeptidase EC 3.4.24.11 has been identified as the initial step in endogenous degradation of ANF. 4 Endopeptidase 24.11 inactivates ANF by cleavage at the cys io5 -phe 106 bond producing an open-ring structure, which our group has identified as being present in significant quantities in human plasma. 5 Parenteral administration of the endopeptidase inhibitor (UK 69578) in animal studies and in humans has resulted in enhanced plasma ANF concentrations with an associated increase in natriuresis and potentiation of biological responses to exogenous ANF. 6 - 8 We have investigated the effects of two doses of an oral prodrug, UK 79300 (which is hydrolyzed to release the active endopeptidase inhibitor UK 73967), on renal and hormonal indexes and blood pressure in a group of healthy volunteers. oeoo FIGURE 
Line graphs showing plasma atrial natriuretic factor (ANF) (mean±SEM) in six normal volunteers receiving placebo (•), 25 mg UK 79300 (A) at 12-hour intervals (top panel), or 50 mg UK 79300 at 12-hour intervals (lower panel). Plasma ANF was significantly elevated on treatment with UK 79300 (p=0.002) with no significant difference between 25 and 50 mg doses (p=0.36). API, activepeptidase inhibitor.
ticipating in the experimental protocol, which had been approved by the Hospital Ethical Committee.
The subjects were studied on two occasions, 2 weeks apart, on days 3 and 4 of identical caffeine-free diets that contained constant amounts of sodium (150 mmol/day) and potassium (80 mmol/day). On each occasion, subjects were admitted to hospital for 2 days during which posture and diet were carefully standardized. Throughout the 48-hour period, subjects received doses of either UK 79300 (Pfizer Central Research, Sandwich, UK) or placebo capsules of identical appearance, taking each for 24 hours (two doses of each at 12-hour intervals, one at 10:00 AM and one at 10:00 PM) in a balanced, randomized study design. Two weeks later, subjects were readmitted for an identical study using the alternative dose of UK 79300 (25 and 50 mg capsules were tested). The balanced, randomized study design ensured that three subjects received 25 mg doses and three subjects 50 mg doses of UK 79300 in the first inpatient study period, and then each received the alternative dose in the second study period. Similarly, in phase 1 three subjects received placebo doses for 24 hours before taking UK 79300 for a further 24 hours, and protocol for the other three subjects was reversed. In the second study phase, all those who had received placebo first in phase 1 were then given UK 79300 for the first 24 hours, and the protocol was reversed for the other three subjects. Thus, all six subjects received both doses, but the order of 25 and 50 mg doses was balanced, and all subjects were studied with placebo preceding administration of UK 79300 on one occasion and following UK 79300 on the other; this order factor was also balanced. This design ensured that no order effects (either of dosing or of placebo versus active agent) could bias results. Blood pressure and heart rate were measured at frequent intervals ( 6-hour samples for measurement of volume, electrolytes, and creatinine in addition to urinary ANF, cyclic guanosine monophosphate (cGMP), aldosterone, and cortisol. Frequent blood samples ( Figures  1 and 2 ) were taken via a 21 gauge "butterfly" cannula secured in a forearm vein for measurement of plasma ANF, plasma renin activity (PRA), aldosterone, cortisol, and catecholamine concentrations.
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Blood samples were taken into chilled tubes with appropriate anticoagulants, plasma was rapidly separated in a chilled centrifuge, and samples were stored at -20° C or -80° C (catecholamines) as appropriate before assay by previously described methods. 9 -13 Total blood volume required per subject by completion of both study phases was 450 ml.
UK 79300 activity at 3 and 7 hours after dose administration was measured (Pfizer Central Research) by bioassay. Neutral endopeptidase was prepared from rat kidney. Unknown inhibitor levels in plasma were inferred from standard curves of extent of hydrolysis of the radiolabeled neutral endopeptidase substrate hippuryl-L-phenylalanyl-Larginine (HPA) (Cambridge Research Chemicals, Cambridge, UK) versus known concentrations of inhibitor.
14 Carbon-14-labeled hippuric acid released from HPA by hydrolysis was acidified, extracted into ethyl acetate, and measured by liquid scintillation counting. 14 In addition, plasma biochemistry (including electrolytes, creatinine, uric acid, glucose, and liver function tests), routine hematology indexes, and dipstick polyurinalysis, were conducted daily.
Blood samples from the first and second study in each volunteer were assayed for hormones in the same run. Variability within assays ranged from 5.0% (coefficient of variation) for aldosterone to 15% for plasma drug activity.
Statistical analysis was conducted using analysis of variance (and covariance where appropriate) with repeated measures (Biomedical Data Processing program 2v) 15 with four variables as repeated measures including treatment (active versus placebo), dose (25 or 50 mg b.i.d.), posture (upright or recumbent), and time. A p value less than 0.05 was taken to indicate statistical significance.
Results
Studies were carried out without complication and data collection was complete. Mean±SEM of 24-hour urinary excretion of sodium was 133 ±4 and 134±5 mmol the day before subjects were admitted to hospital for first and second study phases, respectively (not significant). Mean body weight did not change between studies. Plasma concentrations of the active moiety UK 73967 (as assessed by bioassay) 14 at 3 and 7 hours after the morning dose, were 62 ±20 and 31 ±8 ng/ml with administration of UK 79300 (25 mg) and 120±33 and 36±6 ng/ml after dosing with 50 mg of the inhibitor. Plasma concentrations of ANF were significantly increased above time-matched placebo values by both doses of UK 79300 (Figure 1 ). These effects were superimposed on a pronounced posturerelated diurnal change in plasma ANF with peptide levels doubling soon after subjects assumed the recumbent posture at 9:00 PM (Figure 1 ). Peak enhancement of plasma ANF by UK 79300 occurred at 2-3 hours after dose administration.
Both PRA and plasma aldosterone concentrations were significantly inhibited by UK 79300, although again, no clear dose effect was observed (Figure 2 ). This effect appeared to be confined to the period, when subjects were seated upright, when there was some predose activation of the RAAS. Plasma, cortisol, and catecholamine concentrations were unchanged by UK 79300 (Table 1) . UK 79300 clearly enhanced urinary sodium and cGMP excretion throughout the 24-hour period (Figure 3) . As with other urinary indexes, no dose effect was observed. The mean excess 24-hour excretion of sodium above time-matched placebo values was 81 ±31 and 64±14 mmol for 25 and 50 mg doses of UK 79300, respectively. Excretion of phosphorus was subtly but significantly enhanced and urine volume also tended to rise with the active agent ( Table 1) . Excretion rates of other electrolytes and of creatinine were unchanged by UK 79300 (Table 2 ) as were serial 6-hour or integrated 24-hour endogenous creatinine clearance values (data not shown). Urinary ANF immunoreactivity was enhanced, whereas that of aldosterone was significantly reduced by UK 79300 (Figure 4 ). Urine cortisol was unchanged ( Table 2 ). The endopeptidase inhibitor did not induce any significant changes in blood pressure or heart rate ( Table 3) .
No adverse symptoms were reported by any subject at either dose of UK 79300. Plasma electrolytes, glucose, cTeatinine, uric acid, liver function tests, or routine hematology indexes were unchanged. No Measurements were taken at 6-hour intervals. Values given are mean±SEM. P, placebo; 25, UK 79300 given in 25 mg dose at 12-hour intervals; 50, UK 79300 given in 50 mg dose at 12-hour intervals.
•Values on active treatment and placebo differed significantly for phosphorus (p<0.05) only.
abnormalities were observed on repeated dipstick polyurinalysis. Screening tests of plasma and urine indexes conducted 1 week after the final dose of active agent showed no significant changes.
Discussion
In a group of normal volunteers, inhibition of the neutral metalloendopeptidase EC 3.4.24.11 by an orally active agent, UK 79300, resulted in a subtle but statistically significant enhancement of plasma ANF, a clear natriuresis, an increase in cGMP excretion, and concomitant suppression of RAAS activity. These features closely parallel the reported effects of sustained low dose infusions of exogenous ANF.'Aie The observed mean enhancement of plasma ANF concentrations above time-matched placebo values was little more than 3-5 pmol/1 even at the peak effect of UK 79300. However, data from low dose infusions of ANF in humans and in animals (where changes in plasma ANF concentrations may be undetectable) suggest that, provided such a subtle effect is sufficiently sustained, important biological effects may be observed. 31718 Thus, evidence suggests that the range of significant biological effects documented in the current study may be attributable to the observed rise in plasma ANF concentrations.
However, it must be acknowledged that the neutral metalloendopeptidase EC 3.4.24.11 is capable of in vivo cleavage of a wide range of peptide substrates. These include bradykinin, encephalin, chemotactic peptide, substance P, neurotensin, and gastrin. 19 Conceivably, enhancement of levels of one or more of these potential substrates may have promoted some of the effects observed. However, animal data demonstrate that the natriuresis associated with parenteral administration of the active moiety of UK 79300 is largely abolished by pretreatment with ANF antisera. were mediated specifically by ANF. Blood pressure and heart rate were not affected by UK 79300. This is consistent with data from sustained low dose infusions of ANF in which significant falls in blood pressure did not occur in normotensive men or animals. 16 ' 17 However, a hypotensive effect was observed in hypertensive subjects.
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- 18 It is interesting that the excess sodium excreted at either dose of UK 79300 amounted to approximately 1 mmol/kg over 24 hours, which is similar to the natriuresis observed by Janssen et al 3 in association with a major fall in blood pressure in a group of patients with hypertension who received a prolonged low dose infusion of ANF.
On the basis of our present data, we cannot rule out the possibility that some or all of the renal effects induced by UK 79300 were the result of local inhibition of EC 24.11 in renal tissue rather than mediated via increments in circulating ANF. It is possible that renal EC 24.11 inhibition enhances delivery of ANF to the distal nephron, allowing greater effects on distal sodium transport mechanisms without the necessity for increased circulating ANF. 20 The source of such additional delivery of ANF could be via protection of filtered peptide or of locally generated ANF, as evidence suggests ANF may be synthesized in the renal distal tubules. 21 Although we observed trends toward more pronounced effects on plasma ANF and aldosterone with the higher dose of UK 79300, no statistically significant dose effects were observed. Similarly, other end-organ effects, such as natriuresis, displayed no dose relation. Plasma drug activity was doserelated, although considerable intersubject variability was present.
This suggests the relation between endopeptidase 24.11 inhibition and the consequent hormonal and other effects is not linear and, at the doses of UK 79300 used in the current study, as in other studies, the dose-response curve is nearly flat. Further studies using a wider dose range should clarify this point.
Inhibitors of endopeptidase EC 24.11 have been investigated in the past, principally as potential analgesics because of the importance of the enzyme in metabolizing endogenous opioids. 22 - 24 The finding that ANF is a substrate for EC 3.4.24.11 has stimulated reassessment of older agents as well as development of new inhibitors. 25 Data from animal studies confirm that EC 24.11 inhibition enhances the effect of ANF. Seymour et al 26 documented enhancement of natriuretic, depressor, and cGMP responses to ANF in SHR treated with the EC 24.11 inhibitor SQ 29,072. Sybertz et al 27 observed similar effects using SCH 34826 in deoxycorticosterone-salt rats.
There are presently few data documenting the effects of EC 24.11 inhibition in humans. Northridge et al 8 reported the effects of the parenteral preparation UK 69578 in both normal volunteers and patients with heart failure. In normal volunteers plasma ANF was enhanced but the dose-response relation appeared rather flat. A natriuresis was observed and plasma renin concentrations fell. In contrast to our data, the experiment was limited to a single dose and 12-hour follow-up observation, and no information was provided concerning effects on other urinary electrolytes (other than sodium and potassium), urine creatinine, plasma and urine aldosterone, cGMP, catecholamine values, blood pressure, or heart rate. The data provided was consistent with our own findings. Data concerning orally active inhibitors are even more scant. Gros and colleagues 28 administered two doses of acetorphan to normal volunteers in a placebo-controlled study. The only three end points documented were effects on "encephalinase" activity, plasma ANF, and natriuresis. Peak elevation of plasma ANF (double baseline) occurred at 2 hours after dose administration, coinciding with peak enzyme inhibition. Natriuresis was weakly dose-related, but enzyme inhibition and enhancement of plasma ANF were not. Again, these limited data are consistent with our own findings.
In summary, we have demonstrated enhancement of plasma ANF concentrations in association with natriuresis and suppression of RAAS activity with administration of an orally active inhibitor of endopeptidase EC 3.4.24.11 in humans. The effects of prolonged administration of such agents remain unknown, and the scene is now set for further clarification of the underlying mechanisms of action and also for therapeutic trials of endopeptidase inhibitors in both hypertension and heart failure.
